Literature DB >> 17477798

Targeting host cells harbouring viruses with radiolabeled antibodies.

Arturo Casadevall1, Harris Goldstein, Ekaterina Dadachova.   

Abstract

Existing antiviral therapies produce a therapeutic effect by suppressing viral replication and reducing viral burden and the associated inflammatory reaction. However, infection with many viruses results in chronic infections that cannot be eradicated by the immune response or available antiviral drugs. As viruses are obligate intracellular pathogens, it should be possible to eradicate chronic infections by targeting and eliminating the infected host cells. Radioisotope-conjugated antibodies that specifically bind viral antigens can deliver cytotoxic radiation to virally infected cells. This approach was recently shown to target and eliminate HIV-1-infected cells in vitro and in mouse models, and provides a new approach for eliminating virally infected cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17477798     DOI: 10.1517/14712598.7.5.595

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  10 in total

1.  Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.

Authors:  Rébécca Phaeton; Matthew Harris; Zewei Jiang; Xing Guo Wang; Mark H Einstein; Gary L Goldberg; Arturo Casadevall; Ekaterina Dadachova
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

2.  Radioimmunotherapy of infection with Bi-labeled antibodies.

Authors:  Ekaterina Dadachova
Journal:  Curr Radiopharm       Date:  2008-09-01

3.  Radiolabeled antibodies for therapy of infectious diseases.

Authors:  Ekaterina Dadachova; Arturo Casadevall
Journal:  Microbiol Spectr       Date:  2014-11

4.  The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.

Authors:  Rébécca Phaeton; Xing Guo Wang; Mark H Einstein; Gary L Goldberg; Arturo Casadevall; Ekaterina Dadachova
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 5.  Radioimmunotherapy of infectious diseases.

Authors:  Ekaterina Dadachova; Arturo Casadevall
Journal:  Semin Nucl Med       Date:  2009-03       Impact factor: 4.446

6.  Microbicidal power of alpha radiation in sterilizing germinating Bacillus anthracis spores.

Authors:  Johanna Rivera; Alfred Morgenstern; Frank Bruchertseifer; John F Kearney; Charles L Turnbough; Ekaterina Dadachova; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

7.  Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens.

Authors:  Joshua D Nosanchuk; Ekaterina Dadachova
Journal:  Front Microbiol       Date:  2012-01-12       Impact factor: 5.640

Review 8.  Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.

Authors:  Mike Bray; Michele Di Mascio; Fabian de Kok-Mercado; Daniel J Mollura; Elaine Jagoda
Journal:  Antiviral Res       Date:  2010-08-13       Impact factor: 5.970

9.  Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology.

Authors:  Xing Guo Wang; Ekaterina Revskaya; Ruth A Bryan; Howard D Strickler; Robert D Burk; Arturo Casadevall; Ekaterina Dadachova
Journal:  PLoS One       Date:  2007-10-31       Impact factor: 3.240

10.  Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19.

Authors:  Ekaterina Dadachova
Journal:  J Nucl Med       Date:  2021-05-07       Impact factor: 10.057

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.